सिप्रोफ्लॉक्सासिन और पिरफेनिडोन का इंटरैक्शन

If ciprofloxacin at the dosage of 750 mg twice daily cannot be avoided, dosage reductions are recommended [see Dosage and Administration (2.4) ].

Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment.

Consider dosage reduction with use of ciprofloxacin.

Monitor patients closely when ciprofloxacin is used at a dosage of 250 mg or 500 mg once daily.

Moderate (e.g., ciprofloxacin) and strong inhibitors of CYP1A2 (e.g., fluvoxamine) increase systemic exposure of ESBRIET and may alter the adverse reaction profile of ESBRIET.